• TG Therapeutics reported positive topline Phase 1 results for subcutaneous BRIUMVI in myasthenia gravis, with full data slated for a future medical meeting.
• Patients showed broad, clinically meaningful symptom improvement over time, supporting expansion beyond multiple sclerosis.
• The company started a potentially registration-directed Phase 2 trial testing BRIUMVI as maintenance therapy following efgartigimod induction in adult myasthenia gravis.
• The strategy targets rapid initial symptom control with longer-lasting disease management, aiming to reduce reliance on repeated FcRn inhibitor dosing.
• The Phase 2 study plans to enroll about 120 patients, randomizing responders to BRIUMVI or placebo during a 24-week controlled period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090730PRIMZONEFULLFEED9733828) on June 09, 2026, and is solely responsible for the information contained therein.